Cargando…
Harnessing immunological targets for COVID-19 immunotherapy
COVID-19 is an infectious and highly contagious disease caused by SARS-CoV-2. The immunotherapy strategy has a great potential to develop a permanent cure against COVID-19. Innate immune cells are in constant motion to scan molecular alteration to cells led by microbial infections throughout the bod...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375415/ https://www.ncbi.nlm.nih.gov/pubmed/34447458 http://dx.doi.org/10.2217/fvl-2021-0048 |
_version_ | 1783740310510108672 |
---|---|
author | Mehata, Abhishesh Kumar Viswanadh, Matte Kasi Priya, Vishnu , Vikas Muthu, Madaswamy S |
author_facet | Mehata, Abhishesh Kumar Viswanadh, Matte Kasi Priya, Vishnu , Vikas Muthu, Madaswamy S |
author_sort | Mehata, Abhishesh Kumar |
collection | PubMed |
description | COVID-19 is an infectious and highly contagious disease caused by SARS-CoV-2. The immunotherapy strategy has a great potential to develop a permanent cure against COVID-19. Innate immune cells are in constant motion to scan molecular alteration to cells led by microbial infections throughout the body and helps in clearing invading viruses. Harnessing immunological targets for removing viral infection, generally based on the principle of enhancing the T-cell and protective immune responses. Currently-approved COVID-19 vaccines are mRNA encapsulated in liposomes that stimulate the host immune system to produce antibodies. Given the vital role of innate immunity, harnessing these immune responses opens up new hope for the generation of long-lasting and protective immunity against COVID-19. |
format | Online Article Text |
id | pubmed-8375415 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Future Medicine Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-83754152021-08-24 Harnessing immunological targets for COVID-19 immunotherapy Mehata, Abhishesh Kumar Viswanadh, Matte Kasi Priya, Vishnu , Vikas Muthu, Madaswamy S Future Virol Review COVID-19 is an infectious and highly contagious disease caused by SARS-CoV-2. The immunotherapy strategy has a great potential to develop a permanent cure against COVID-19. Innate immune cells are in constant motion to scan molecular alteration to cells led by microbial infections throughout the body and helps in clearing invading viruses. Harnessing immunological targets for removing viral infection, generally based on the principle of enhancing the T-cell and protective immune responses. Currently-approved COVID-19 vaccines are mRNA encapsulated in liposomes that stimulate the host immune system to produce antibodies. Given the vital role of innate immunity, harnessing these immune responses opens up new hope for the generation of long-lasting and protective immunity against COVID-19. Future Medicine Ltd 2021-08-09 2021-07 /pmc/articles/PMC8375415/ /pubmed/34447458 http://dx.doi.org/10.2217/fvl-2021-0048 Text en © 2021 Future Medicine Ltd https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Review Mehata, Abhishesh Kumar Viswanadh, Matte Kasi Priya, Vishnu , Vikas Muthu, Madaswamy S Harnessing immunological targets for COVID-19 immunotherapy |
title | Harnessing immunological targets for COVID-19 immunotherapy |
title_full | Harnessing immunological targets for COVID-19 immunotherapy |
title_fullStr | Harnessing immunological targets for COVID-19 immunotherapy |
title_full_unstemmed | Harnessing immunological targets for COVID-19 immunotherapy |
title_short | Harnessing immunological targets for COVID-19 immunotherapy |
title_sort | harnessing immunological targets for covid-19 immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375415/ https://www.ncbi.nlm.nih.gov/pubmed/34447458 http://dx.doi.org/10.2217/fvl-2021-0048 |
work_keys_str_mv | AT mehataabhisheshkumar harnessingimmunologicaltargetsforcovid19immunotherapy AT viswanadhmattekasi harnessingimmunologicaltargetsforcovid19immunotherapy AT priyavishnu harnessingimmunologicaltargetsforcovid19immunotherapy AT vikas harnessingimmunologicaltargetsforcovid19immunotherapy AT muthumadaswamys harnessingimmunologicaltargetsforcovid19immunotherapy |